CAR-T’s against the CD-19 protein have been approved for acute lymphoblastic leukemia (ALL, Kymriah) (51, 52) or other types of B-cell lymphomas (Yescarta) (53). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.